Dermatitis

Allergic Contact Dermatitis Due to "Therapeutic Uses" of Tea Tree Oil on the Lips and Toenails No abstract available

Cutaneous Vasculitis Caused by Clindamycin No abstract available

Patch Testing in Saudi Arabia No abstract available

Self-Reported Hand Eczema: Assessment of Prevalence and Risk Factors in Health Care Versus Non–Health Care Workers During the COVID-19 Pandemic No abstract available

High Levels of Psychological Distress, Sleep Disturbance, and Alcohol Use Disorder in Adults With Atopic Dermatitis Background The burden of illness associated with atopic dermatitis (AD) is significant and multidimensional, especially in those with moderate to severe disease. Objective Our objective was to evaluate the disease burden of patients with AD in relation to psychological distress, sleep disturbance, and alcohol misuse. Methods Patients with AD, attending 2 tertiary referral centers in Dublin, Ireland, were recruited. A series of validated questionnaires were used including the Patient-Oriented Eczema Measure, Dermatology Life Quality Index (DLQI), Center for Epidemiologic Studies–Depression Scale, Quality of Life in Atopic Dermatitis Questionnaire, Alcohol Use Disorders Identification Test, and Pittsburgh Sleep Quality Index. The Eczema Area and Severity Index was calculated contemporaneously with the questionnaire completion. Results One hundred patients completed the questionnaire, of whom 52% were female. Sixty-three percent of patients experienced impaired quality of life as measured by the DLQI. Higher DLQI scores correlated with decreasing age (r = 0.3277, P < 0.0009). Thirty percent were found to be at risk of clinical depression, and higher Center for Epidemiologic Studies–Depression Scale scores correlated with a younger age and eczema severity. Sleep disturbance was greater in those at risk of depression (mean = 10.40 vs 5.79, P < 0.0001). Patients with moderate to severe AD were more likely to score higher on the Alcohol Use Disorders Identification Test, and 25% met the criteria for alcohol use disorder. In relation to sleep, 73% of patients scored higher than 5 on the Pittsburgh Sleep Quality Index, which signifies poor sleep quality. Conclusions Patients with AD endure a significant burden on health with regard to mental well-being, alcohol use, and sleep quality. Clinicians should consider screening patients for these comorbidities. Address reprint requests to Eimear Gilhooley, MSc, Dermatology Department, Tallaght University Hospital, Dublin 24, Ireland. E-mail: gilhooec@tcd.ie. The authors have no funding or conflicts of interest to declare. © 2020 American Contact Dermatitis Society

Dupilumab in Elderly Patients With Severe Atopic Dermatitis Background Atopic dermatitis (AD) in the elderly has been poorly investigated, although its incidence is gradually increasing mainly in industrialized countries. Age-specific factors in older patients must be considered when selecting treatment options. Objectives To evaluate the efficacy and tolerability of dupilumab in treating elderly patients with severe AD. Methods This was a retrospective, multicenter study involving 26 elderly patients (age, ≥65 years) with severe AD who were treated with dupilumab for at least 16 weeks. Absolute and percentage frequencies were used to evaluate qualitative variables and mean and SD for quantitative ones. For Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI), the median was also calculated. Wilcoxon test was used to evaluate the variations in EASI, Pruritus NRS, and DLQI observed between the 2 examinations. Results After 4 months of therapy, the majority of patients showed a significant improvement in EASI (64.4%), Pruritus NRS (58.2%), and DLQI (44.9%). Only 11% of patients reported mild or moderate conjunctivitis. Conclusions To the best of our knowledge, this is the first study concerning the use of dupilumab in the elderly with severe AD. Our data show the effectiveness of dupilumab in this particular population with a lower percentage of conjunctivitis than observed in studies on adults and also excellent control of itching. Only larger, controlled case studies will be able to clarify whether the dosage or frequency of administration of dupilumab in these patients should be different from the protocol used for adults. Address reprint requests to Filomena Russo, MD, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, 53100 Siena, Italy. E-mail: file.russo@libero.it. The authors have no funding or conflicts of interest to declare. © 2020 American Contact Dermatitis Society

Low Vitamin D Levels in Breast Milk May Be a Risk Factor for Atopic Dermatitis Flare-up During Infancy No abstract available

Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States Background Atopic dermatitis (AD) is associated with considerable financial cost. However, the full burden of out-of-pocket (OOP) expenses is not well understood. Objective We sought to characterize the OOP health care expenses associated with AD management. Methods A 25-question voluntary online survey was administered to National Eczema Association members worldwide (n = 113,502). Inclusion criteria (US residents age ≥18 years who either self-reported had AD or were primary caregivers of individuals with AD) were met by 77.3% (1118/1447) of respondents. Results Respondents reported OOP expenses in 3 categories: (1) health care providers and prescriptions, including health care provider visit deductibles (68.7% [686]), prescription co-pays (64.3% [635]), and prescriptions not covered by insurance (48.6% [468]); (2) nonprescription health care products, including moisturizers (94.3% [934]), hygiene products (85.0% [824], allergy medications (75.1% [715]), itch relievers (68.25% [647]), dietary supplements (52.2% [491]), and sleep aids (37.0% [336]); and (3) complementary approaches, including cleaning products (74.7% [732]), clothing/bedding (44.8% [430]), alternative medications (19.0% [180]), and adjunctive therapies (15.9% [150]). The median annual AD OOP expense was US $600 (range, US $0–$200,000), with 41.9% (364) reporting expenditures US $1000 or greater. Conclusions Out-of-pocket expenses place a significant financial burden on individuals with AD. Additional studies are needed to better understand associations and impact of OOP costs. Address reprint requests to Wendy Smith Begolka, MBS, National Eczema Association, #B300, 505 San Marin Dr, Novato, CA 94945. E-mail: wendy@nationaleczema.org. W.S.B. and R.C. contributed to this work equally. W.S.B. had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. W.S.B., I.J.T., and J.I.S. participated in the study concept and design. W.S.B. and I.J.T. participated in the acquisition of data. W.S.B., R.C., I.J.T., and J.I.S. participated in the analysis and interpretation of data. W.S.B., R.C., I.J.T., and J.I.S. participated in the drafting of the article. W.S.B., R.C., I.J.T., and J.I.S. participated in the critical revision of the manuscript for important intellectual content. W.S.B., R.C., I.J.T., and J.I.S. participated in the statistical analysis. Funding support was received from National Eczema Association. R.C. reports personal fees from Abbvie and RegeneronSanofi. J.S. reports personal fees from Abbvie, Anaptysbio, Asana, EliLilly, Galderma, GlaxoSmithKline, Kiniksa, Leo, Menlo, Pfizer, Realm, Regeneron­Sanofi, and Roivant, and grants from GlaxoSmithKline, Regeneron­Sanofi, and Galderma. The other authors have no conflicts of interest to declare. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. © 2020 American Contact Dermatitis Society

Allergic Contact Cheilitis and Stomatitis Due to Triclosan in Toothpaste No abstract available

YouTube as a Source of Information on Contact Dermatitis No abstract available

#

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Telephone consultation 11855 int 1193,